Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 189 Shares of Haemonetics Co. (NYSE:HAE)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 1.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,092 shares of the medical instruments supplier’s stock after selling 189 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Haemonetics were worth $866,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Xponance Inc. grew its stake in shares of Haemonetics by 5.9% during the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier’s stock worth $566,000 after purchasing an additional 404 shares during the period. Boston Partners grew its position in shares of Haemonetics by 27.5% during the 4th quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier’s stock worth $41,485,000 after buying an additional 115,506 shares during the period. Intech Investment Management LLC increased its stake in shares of Haemonetics by 107.5% in the 4th quarter. Intech Investment Management LLC now owns 46,338 shares of the medical instruments supplier’s stock valued at $3,618,000 after acquiring an additional 24,009 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after acquiring an additional 164,111 shares during the period. Finally, William Blair Investment Management LLC boosted its stake in Haemonetics by 29.6% during the 4th quarter. William Blair Investment Management LLC now owns 446,258 shares of the medical instruments supplier’s stock worth $34,844,000 after acquiring an additional 101,807 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 1.6 %

NYSE HAE opened at $64.35 on Thursday. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock’s 50 day moving average price is $66.45 and its two-hundred day moving average price is $74.82. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of 25.33, a PEG ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on HAE. JMP Securities lowered their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Needham & Company LLC decreased their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.